Atomoxetine (BioDeep_00000018058)

   

human metabolite blood metabolite Chemicals and Drugs Volatile Flavor Compounds


代谢物信息卡片


N-METHYL-GAMMA-(2-METHYLPHENOXY)BENZENEPROPANAMINE HYDROCHLORIDE

化学式: C17H21NO (255.1623056)
中文名称: 托莫西汀
谱图信息: 最多检出来源 Homo sapiens(blood) 10%

分子结构信息

SMILES: CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2
InChI: InChI=1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3/t17-/m1/s1

描述信息

Atomoxetine is the first non-stimulant drug approved for the treatment of attention-deficit hyperactivity disorder (ADHD). It is sold in the form of the hydrochloride salt of atomoxetine. This chemical is manufactured and marketed under the brand name Strattera; by Eli Lilly and Company and as a generic Attentin by Torrent Pharmaceuticals. There is currently no generic available within the United States due to patent restrictions. [Wikipedia]
N - Nervous system > N06 - Psychoanaleptics > N06B - Psychostimulants, agents used for adhd and nootropics > N06BA - Centrally acting sympathomimetics
D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D018759 - Adrenergic Uptake Inhibitors
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C185721 - Norepinephrine Reuptake Inhibitor
C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent
D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents
D049990 - Membrane Transport Modulators

同义名列表

17 个代谢物同义名

N-METHYL-GAMMA-(2-METHYLPHENOXY)BENZENEPROPANAMINE HYDROCHLORIDE; methyl[(3R)-3-(2-methylphenoxy)-3-phenylpropyl]amine; Tomoxetine hydrochloride, (+)-isomer - T351671; Tomoxetine hydrochloride, (+-)-isomer; Tomoxetine hydrochloride, (-)-isomer; Hydrochloride, atomoxetine; Atomoxetine Hydrochloride; HCL, Atomoxetine; Atomoxetine HCL; (-)-Tomoxetine; Atomoxetine; Tomoxetinum; Tomoxetine; Tomoxetina; Strattera; Tomoxetine; Atomoxetine



数据库引用编号

13 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Susu Qu, Xiangyu Zhou, Zhicheng Wang, Yi Wei, Han Zhou, Xinshuang Zhang, Qingjie Zhu, Yanmin Wang, Quanjun Yang, Likun Jiang, Yuan Ma, Yuan Gao, Lei Kong, Li Zhang. The effects of methylphenidate and atomoxetine on Drosophila brain at single-cell resolution and potential drug repurposing for ADHD treatment. Molecular psychiatry. 2023 Nov; ?(?):. doi: 10.1038/s41380-023-02314-6. [PMID: 37957291]
  • Xiaojing Hu, Lili Pan, Wenjie Li. Meta-analysis on the efficacy of the norepinephrine reuptake inhibitors reboxetine and atomoxetine for the treatment of schizophrenia and attention deficit hyperactivity disorder. Advances in clinical and experimental medicine : official organ Wroclaw Medical University. 2022 Nov; ?(?):. doi: 10.17219/acem/155802. [PMID: 36449401]
  • Esra Demirci, Elif Funda Sener, Melike Kevser Gul, Muge Gulcihan Onal, Fatma Dal. A view of response and resistance to atomoxetine treatment in children with ADHD: effects of CYP2C19 polymorphisms and BDNF levels. European journal of clinical pharmacology. 2022 Jul; 78(7):1095-1104. doi: 10.1007/s00228-022-03321-2. [PMID: 35486119]
  • Katrin Ruppert, Christoph Geffert, Hans-Willi Clement, Christian Bachmann, Michael Haberhausen, Eberhard Schulz, Christian Fleischhaker, Monica Biscaldi-Schäfer. Therapeutic drug monitoring of atomoxetine in children and adolescents with attention-deficit/ hyperactivity disorder: a naturalistic study. Journal of neural transmission (Vienna, Austria : 1996). 2022 Jul; 129(7):945-959. doi: 10.1007/s00702-022-02483-8. [PMID: 35391568]
  • Allan I Levey, Deqiang Qiu, Liping Zhao, William T Hu, Duc M Duong, Lenora Higginbotham, Eric B Dammer, Nicholas T Seyfried, Thomas S Wingo, Chadwick M Hales, Malú Gámez Tansey, David S Goldstein, Anees Abrol, Vince D Calhoun, Felicia C Goldstein, Ihab Hajjar, Anne M Fagan, Doug Galasko, Steven D Edland, John Hanfelt, James J Lah, David Weinshenker. A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment. Brain : a journal of neurology. 2022 Jun; 145(6):1924-1938. doi: 10.1093/brain/awab452. [PMID: 34919634]
  • Melike Kevser Gul, Elif Funda Sener, Muge Gulcihan Onal, Esra Demirci. Role of the norepinephrine transporter polymorphisms in atomoxetine treatment: From response to side effects in children with ADHD. Journal of psychopharmacology (Oxford, England). 2022 06; 36(6):715-722. doi: 10.1177/02698811211015245. [PMID: 33944622]
  • Himanshu Aggarwal, Surbhi Gupta, Poonam Sharma, B M Sharma, Bhupesh Sharma. Neurobehavioral and neurobiochemical effect of atomoxetine and N-acetylcysteine in streptozotocin diabetes induced endothelial dysfunction and related dementia. Physiology & behavior. 2022 05; 249(?):113767. doi: 10.1016/j.physbeh.2022.113767. [PMID: 35245527]
  • Fahad Aldosary, Sandhaya Norris, Philippe Tremblay, Jonathan S James, James C Ritchie, Pierre Blier. Differential Potency of Venlafaxine, Paroxetine, and Atomoxetine to Inhibit Serotonin and Norepinephrine Reuptake in Patients With Major Depressive Disorder. The international journal of neuropsychopharmacology. 2022 04; 25(4):283-292. doi: 10.1093/ijnp/pyab086. [PMID: 34958348]
  • Mo'tasem M Alsmadi, Laith N Al Eitan, Nasir M Idkaidek, Karem H Alzoubi. The Development of a PBPK Model for Atomoxetine Using Levels in Plasma, Saliva and Brain Extracellular Fluid in Patients with Normal and Deteriorated Kidney Function. CNS & neurological disorders drug targets. 2022; 21(8):704-716. doi: 10.2174/1871527320666210621102437. [PMID: 35043773]
  • Ian R McGrane, Trevor J Campbell. Probable Genitourinary Adverse Events Associated With Atomoxetine in an Adult Male: A Case Report. Journal of pharmacy practice. 2021 Dec; 34(6):962-965. doi: 10.1177/0897190020953022. [PMID: 32862763]
  • Yutong You, Xu Wang, Kaiqi Ma, Jiaru Li, Ying Peng, Jiang Zheng. Metabolic Activation of Atomoxetine Mediated by Cytochrome P450 2D6. Chemical research in toxicology. 2021 09; 34(9):2135-2144. doi: 10.1021/acs.chemrestox.1c00216. [PMID: 34431675]
  • Atsunori Sugimoto, Yutaro Suzuki, Naoki Orime, Taketsugu Hayashi, Kiyohiro Yoshinaga, Jun Egawa, Shin Ono, Takuro Sugai, Yoshimasa Inoue, Toshiyuki Someya. The lowest effective plasma concentration of atomoxetine in pediatric patients with attention deficit/hyperactivity disorder: A non-randomized prospective interventional study. Medicine. 2021 Jul; 100(27):e26552. doi: 10.1097/md.0000000000026552. [PMID: 34232195]
  • Ying Xia, Hong-Li Guo, Ya-Hui Hu, Jia-Yi Long, Jing Chen, Feng Chen, Xing Ji. Determination of atomoxetine levels in human plasma using LC-MS/MS and clinical application to Chinese children with ADHD based on CPIC guidelines. Analytical methods : advancing methods and applications. 2021 06; 13(21):2434-2441. doi: 10.1039/d1ay00521a. [PMID: 33998618]
  • Fatma Gür, Bahri Gür, Beyzagül Erkayman, Zekai Halıcı, Akar Karakoç. Investigation of serum and brain superoxide dismutase levels depending on atomoxetine used in attention-deficit/hyperactivity disorder treatment: A combination of in vivo and molecular docking studies. Bioorganic chemistry. 2020 12; 105(?):104435. doi: 10.1016/j.bioorg.2020.104435. [PMID: 33161254]
  • Eui Hyun Jung, Yun Jeong Lee, Dong-Hyun Kim, Pureum Kang, Chang Woo Lim, Chang-Keun Cho, Choon-Gon Jang, Seok-Yong Lee, Jung-Woo Bae. Effects of paroxetine on the pharmacokinetics of atomoxetine and its metabolites in different CYP2D6 genotypes. Archives of pharmacal research. 2020 Dec; 43(12):1356-1363. doi: 10.1007/s12272-020-01300-8. [PMID: 33245517]
  • Jens Teichert, James B Rowe, Karen D Ersche, Nikolina Skandali, Julia Sacher, Achim Aigner, Ralf Regenthal. Determination of atomoxetine or escitalopram in human plasma by HPLC: Applications in neuroscience research studies
. International journal of clinical pharmacology and therapeutics. 2020 Aug; 58(8):426-438. doi: 10.5414/cp203705. [PMID: 32449675]
  • Emrah Gün, Kenan Kocabay. Use of Intravenous Lipid Emulsion Therapy in a Case of Atomoxetine (Strattera®) Toxicity. The Journal of emergency medicine. 2020 Aug; 59(2):e49-e51. doi: 10.1016/j.jemermed.2020.04.042. [PMID: 32505448]
  • Yadan Zhang, Liao Shen, Tao Wang, Haiyan Li, Ri Huang, Zhen Zhang, Yongan Wang, Dongqin Quan. Taste masking of water-soluble drug by solid lipid microspheres: a child-friendly system established by reversed lipid-based nanoparticle technique. The Journal of pharmacy and pharmacology. 2020 Jun; 72(6):776-786. doi: 10.1111/jphp.13245. [PMID: 32153037]
  • Shiho Suzuki, Ryo Kimura, Shingo Maegawa, Masatoshi Nakata, Masatoshi Hagiwara. Different effects of methylphenidate and atomoxetine on the behavior and brain transcriptome of zebrafish. Molecular brain. 2020 05; 13(1):70. doi: 10.1186/s13041-020-00614-4. [PMID: 32375837]
  • Yuki Notsu, Makiko Shimizu, Tatsuro Sasaki, Ayane Nakano, Miki Ota, Sayaka Yoshida, Hiroshi Yamazaki. Simple pharmacokinetic models accounting for drug monitoring results of atomoxetine and its 4-hydroxylated metabolites in Japanese pediatric patients genotyped for cytochrome P450 2D6. Drug metabolism and pharmacokinetics. 2020 Apr; 35(2):191-200. doi: 10.1016/j.dmpk.2019.08.005. [PMID: 32184039]
  • Atsunori Sugimoto, Yutaro Suzuki, Naoki Orime, Taketsugu Hayashi, Jun Egawa, Takuro Sugai, Yoshimasa Inoue, Toshiyuki Someya. Non-Linear Pharmacokinetics of Atomoxetine in Adult Japanese Patients With ADHD. Journal of attention disorders. 2020 02; 24(3):490-493. doi: 10.1177/1087054716661235. [PMID: 27474159]
  • Fan Zhang, Ping Zhu, Li-Hui Wu. [Association of microRNA expression before and after drug therapy with clinical symptoms in children with attention deficit hyperactivity disorder]. Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics. 2020 Feb; 22(2):152-157. doi: NULL. [PMID: 32051083]
  • Madeline M Pantoni, Stephanie A Carmack, Leen Hammam, Stephan G Anagnostaras. Dopamine and norepinephrine transporter inhibition for long-term fear memory enhancement. Behavioural brain research. 2020 01; 378(?):112266. doi: 10.1016/j.bbr.2019.112266. [PMID: 31580915]
  • Ali Rabiey, Peyman Hassani-Abharian, Majid Farhad, Ali Reza Moravveji, Goodarz Akasheh, Hamid Reza Banafshe. Atomoxetine Efficacy in Methamphetamine Dependence during Methadone Maintenance Therapy. Archives of Iranian medicine. 2019 12; 22(12):692-698. doi: NULL. [PMID: 31823620]
  • Courtney A Marshall, Zachary D Brodnik, Ole V Mortensen, Maarten E A Reith, Jed S Shumsky, Barry D Waterhouse, Rodrigo A España, Sandhya Kortagere. Selective activation of Dopamine D3 receptors and norepinephrine transporter blockade enhances sustained attention. Neuropharmacology. 2019 04; 148(?):178-188. doi: 10.1016/j.neuropharm.2019.01.003. [PMID: 30633928]
  • Pengfei Cao, Linxiao Wang, Qi Cheng, Xiaojing Sun, Qi Kang, Libin Dai, Xianju Zhou, Zixiang Song. Changes in serum miRNA-let-7 level in children with attention deficit hyperactivity disorder treated by repetitive transcranial magnetic stimulation or atomoxetine: An exploratory trial. Psychiatry research. 2019 04; 274(?):189-194. doi: 10.1016/j.psychres.2019.02.037. [PMID: 30807970]
  • Danielly Chierrito, Camila B Villas-Boas, Fernanda S Tonin, Fernando Fernandez-Llimos, Andréia C C Sanches, João C P de Mello. Using Cell Cultures for the Investigation of Treatments for Attention Deficit Hyperactivity Disorder: A Systematic Review. Current neuropharmacology. 2019; 17(10):916-925. doi: 10.2174/1570159x17666190409143155. [PMID: 31079591]
  • Mahdi Ghorbani, Mahmoud Chamsaz, Mohsen Aghamohammadhasan, Alireza Shams. Ultrasonic assisted magnetic dispersive solid phase microextraction for pre concentration of serotonin-norepinephrine reuptake inhibitor drugs. Analytical biochemistry. 2018 06; 551(?):7-18. doi: 10.1016/j.ab.2018.05.003. [PMID: 29750941]
  • Richard S Schottenfeld, Marek C Chawarski, Mehmet Sofuoglu, Weng-Tink Chooi, Norzarina M Zaharim, M Azhar M Yasin, Imran Ahmad, Sharifah Zubaidiah Syed Jaapar, B Kasinather Vicknasingam. Atomoxetine for amphetamine-type stimulant dependence during buprenorphine treatment: A randomized controlled trial. Drug and alcohol dependence. 2018 05; 186(?):130-137. doi: 10.1016/j.drugalcdep.2018.01.017. [PMID: 29573648]
  • Weize Huang, Mariko Nakano, Jennifer Sager, Isabelle Ragueneau-Majlessi, Nina Isoherranen. Physiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions. Drug metabolism and disposition: the biological fate of chemicals. 2017 11; 45(11):1156-1165. doi: 10.1124/dmd.117.076455. [PMID: 28860113]
  • Tian Lan, Xiao-Xia Hu, Bing-Qing Liang, Wen-He Pan, Quan Zhou, Ling-Jing Yuan, Guo-Xin Hu. The Effect of Myricetin on Pharmacokinetics of Atomoxetine and its Metabolite 4-Hydroxyatomoxetine In Vivo and In Vitro. European journal of drug metabolism and pharmacokinetics. 2017 Apr; 42(2):261-268. doi: 10.1007/s13318-016-0347-0. [PMID: 27207674]
  • Yutaro Suzuki, Misuzu Tajiri, Atsunori Sugimoto, Naoki Orime, Taketsugu Hayashi, Jun Egawa, Takuro Sugai, Yoshimasa Inoue, Toshiyuki Someya. Sex Differences in the Effect of Atomoxetine on the QT Interval in Adult Patients With Attention-Deficit Hyperactivity Disorder. Journal of clinical psychopharmacology. 2017 Feb; 37(1):27-31. doi: 10.1097/jcp.0000000000000630. [PMID: 27984328]
  • Christopher M Warren, Robert C Wilson, Nic J van der Wee, Eric J Giltay, Martijn S van Noorden, Jonathan D Cohen, Sander Nieuwenhuis. The effect of atomoxetine on random and directed exploration in humans. PloS one. 2017; 12(4):e0176034. doi: 10.1371/journal.pone.0176034. [PMID: 28445519]
  • Peter R Bieck, Mark Leibowitz, D Richard Lachno, Edouard Ledent, Robert Padich, Stan Jhee. Dihydroxyphenylglycol as a Biomarker of Norepinephrine Transporter Inhibition by Atomoxetine: Human Model to Assess Central and Peripheral Effects of Dosing. Journal of clinical psychopharmacology. 2016 Dec; 36(6):675-683. doi: 10.1097/jcp.0000000000000611. [PMID: 27755221]
  • Masako Nakano, Jennifer Witcher, Yoichi Satoi, Taro Goto. Pharmacokinetic Profile and Palatability of Atomoxetine Oral Solution in Healthy Japanese Male Adults. Clinical drug investigation. 2016 Nov; 36(11):903-911. doi: 10.1007/s40261-016-0430-y. [PMID: 27444039]
  • Nikol Pribilova, Ivo Paclt, Patricie Kollarova, Milada Kohoutova, Monika Dezortova, Milan Hajek, Ladislav Csemy. Long term pharmacotherapy by methylfenidate or atomoxetine DAT 1 10/10 ADHD children in correlation with results of the imaging methods. Neuro endocrinology letters. 2016 Sep; 37(4):289-294. doi: NULL. [PMID: 27857045]
  • Charlotte L Rae, Cristina Nombela, Patricia Vázquez Rodríguez, Zheng Ye, Laura E Hughes, P Simon Jones, Timothy Ham, Timothy Rittman, Ian Coyle-Gilchrist, Ralf Regenthal, Barbara J Sahakian, Roger A Barker, Trevor W Robbins, James B Rowe. Atomoxetine restores the response inhibition network in Parkinson's disease. Brain : a journal of neurology. 2016 08; 139(Pt 8):2235-48. doi: 10.1093/brain/aww138. [PMID: 27343257]
  • Jean C Dinh, Robin E Pearce, Leon Van Haandel, Andrea Gaedigk, J Steven Leeder. Characterization of Atomoxetine Biotransformation and Implications for Development of PBPK Models for Dose Individualization in Children. Drug metabolism and disposition: the biological fate of chemicals. 2016 07; 44(7):1070-9. doi: 10.1124/dmd.116.069518. [PMID: 27052878]
  • Sarah E Bradshaw, Kara L Agster, Barry D Waterhouse, Jill A McGaughy. Age-related changes in prefrontal norepinephrine transporter density: The basis for improved cognitive flexibility after low doses of atomoxetine in adolescent rats. Brain research. 2016 Jun; 1641(Pt B):245-57. doi: 10.1016/j.brainres.2016.01.001. [PMID: 26774596]
  • J T Brown, S M Abdel-Rahman, L van Haandel, A Gaedigk, Y S Lin, J S Leeder. Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD. Clinical pharmacology and therapeutics. 2016 06; 99(6):642-50. doi: 10.1002/cpt.319. [PMID: 26660002]
  • Guoxun Zheng, Weiwei Xue, Panpan Wang, Fengyuan Yang, Bo Li, Xiaofeng Li, Yinghong Li, Xiaojun Yao, Feng Zhu. Exploring the Inhibitory Mechanism of Approved Selective Norepinephrine Reuptake Inhibitors and Reboxetine Enantiomers by Molecular Dynamics Study. Scientific reports. 2016 05; 6(?):26883. doi: 10.1038/srep26883. [PMID: 27230580]
  • Guo Yu, Guo-Fu Li, John S Markowitz. Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition. Journal of child and adolescent psychopharmacology. 2016 05; 26(4):314-26. doi: 10.1089/cap.2015.0137. [PMID: 26859445]
  • Ioana Todor, Adina Popa, Maria Neag, Dana Muntean, Corina Bocsan, Anca Buzoianu, Laurian Vlase, Ana-Maria Gheldiu, Corina Briciu. Evaluation of a Potential Metabolism-Mediated Drug-Drug Interaction Between Atomoxetine and Bupropion in Healthy Volunteers. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques. 2016 Apr; 19(2):198-207. doi: 10.18433/j3h03r. [PMID: 27518170]
  • Benedikt Stegmann, Anett Dörfelt, Ekkehard Haen. Quantification of Methylphenidate, Dexamphetamine, and Atomoxetine in Human Serum and Oral Fluid by HPLC With Fluorescence Detection. Therapeutic drug monitoring. 2016 Feb; 38(1):98-107. doi: 10.1097/ftd.0000000000000245. [PMID: 26349081]
  • William Kielbasa, Evelyn Lobo. Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. Journal of clinical pharmacology. 2015 Dec; 55(12):1422-31. doi: 10.1002/jcph.551. [PMID: 26011686]
  • David B Clemow, Chris J Bushe. Atomoxetine in patients with ADHD: A clinical and pharmacological review of the onset, trajectory, duration of response and implications for patients. Journal of psychopharmacology (Oxford, England). 2015 Dec; 29(12):1221-30. doi: 10.1177/0269881115602489. [PMID: 26349559]
  • Ji-Yeong Byeon, Young-Hoon Kim, Han-Sung Na, Jong-Hwa Jang, Se-Hyung Kim, Yun-Jeong Lee, Jung-Woo Bae, In Su Kim, Choon-Gon Jang, Myeon-Woo Chung, Seok-Yong Lee. Effects of the CYP2D6*10 allele on the pharmacokinetics of atomoxetine and its metabolites. Archives of pharmacal research. 2015 Nov; 38(11):2083-91. doi: 10.1007/s12272-015-0646-z. [PMID: 26254792]
  • Shen Zhang, Changhong Ding, Husheng Wu, Fang Fang, Xiaohui Wang, Xiaotun Ren. [Clinical effect of atomoxetine hydrochloride in 66 children with narcolepsy]. Zhonghua er ke za zhi = Chinese journal of pediatrics. 2015 Oct; 53(10):760-4. doi: NULL. [PMID: 26758112]
  • William Kielbasa, Alan Pan, Alvaro Pereira. A pharmacokinetic/pharmacodynamic investigation: assessment of edivoxetine and atomoxetine on systemic and central 3,4-dihydroxyphenylglycol, a biochemical marker for norepinephrine transporter inhibition. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2015 Mar; 25(3):377-85. doi: 10.1016/j.euroneuro.2014.12.009. [PMID: 25637266]
  • Hua-jin Zeng, Ran Yang, Ying Zhang, Jian-jun Li, Ling-bo Qu. Capillary electrophoresis coupled with electrochemiluminescence for determination of atomoxetine hydrochloride and the study on its interactions with three proteins. Luminescence : the journal of biological and chemical luminescence. 2015 Mar; 30(2):124-30. doi: 10.1002/bio.2700. [PMID: 25044877]
  • Jens Jordan, Cyndya Shibao, Italo Biaggioni. Multiple system atrophy: using clinical pharmacology to reveal pathophysiology. Clinical autonomic research : official journal of the Clinical Autonomic Research Society. 2015 Feb; 25(1):53-9. doi: 10.1007/s10286-015-0271-4. [PMID: 25757803]
  • Yia-Ping Liu, Teng-Shun Huang, Che-Se Tung, Chen-Cheng Lin. Effects of atomoxetine on attention and impulsivity in the five-choice serial reaction time task in rats with lesions of dorsal noradrenergic ascending bundle. Progress in neuro-psychopharmacology & biological psychiatry. 2015 Jan; 56(?):81-90. doi: 10.1016/j.pnpbp.2014.08.007. [PMID: 25151304]
  • Mark E Bangs, Linda A Wietecha, Shufang Wang, Andrew S Buchanan, Douglas K Kelsey. Meta-analysis of suicide-related behavior or ideation in child, adolescent, and adult patients treated with atomoxetine. Journal of child and adolescent psychopharmacology. 2014 Oct; 24(8):426-34. doi: 10.1089/cap.2014.0005. [PMID: 25019647]
  • Angie A Kehagia, Charlotte R Housden, Ralf Regenthal, Roger A Barker, Ulrich Müller, James Rowe, Barbara J Sahakian, Trevor W Robbins. Targeting impulsivity in Parkinson's disease using atomoxetine. Brain : a journal of neurology. 2014 Jul; 137(Pt 7):1986-97. doi: 10.1093/brain/awu117. [PMID: 24893708]
  • Surbhi Gupta, Bhupesh Sharma, Prabhat Singh, Brij Mohan Sharma. Modulation of transient receptor potential vanilloid subtype 1 (TRPV1) and norepinephrine transporters (NET) protect against oxidative stress, cellular injury, and vascular dementia. Current neurovascular research. 2014 May; 11(2):94-106. doi: 10.2174/1567202611666140305221854. [PMID: 24597602]
  • Josep Antoni Ramos-Quiroga, Margarida Corominas-Roso, Gloria Palomar, Nuria Gomez-Barros, Marta Ribases, Cristina Sanchez-Mora, Rosa Bosch, Mariana Nogueira, Montserrat Corrales, Sergi Valero, Miguel Casas. Changes in the serum levels of brain-derived neurotrophic factor in adults with attention deficit hyperactivity disorder after treatment with atomoxetine. Psychopharmacology. 2014 Apr; 231(7):1389-95. doi: 10.1007/s00213-013-3343-y. [PMID: 24202115]
  • Y-S Ding, M Naganawa, J-D Gallezot, N Nabulsi, S-F Lin, J Ropchan, D Weinzimmer, T J McCarthy, R E Carson, Y Huang, M Laruelle. Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: Implications on treatment of depression and ADHD. NeuroImage. 2014 Feb; 86(?):164-71. doi: 10.1016/j.neuroimage.2013.08.001. [PMID: 23933039]
  • Chang-Ik Choi, Jung-Woo Bae, Yun-Jeong Lee, Hye-In Lee, Choon-Gon Jang, Seok-Yong Lee. Effects of CYP2C19 genetic polymorphisms on atomoxetine pharmacokinetics. Journal of clinical psychopharmacology. 2014 Feb; 34(1):139-42. doi: 10.1097/jcp.0b013e3182a608a2. [PMID: 24346747]
  • Thomas Del'Guidice, Morgane Lemasson, Adeline Etiévant, Stella Manta, Luiz Alexandre V Magno, Guy Escoffier, François S Roman, Jean-Martin Beaulieu. Dissociations between cognitive and motor effects of psychostimulants and atomoxetine in hyperactive DAT-KO mice. Psychopharmacology. 2014 Jan; 231(1):109-22. doi: 10.1007/s00213-013-3212-8. [PMID: 23912772]
  • Sucharita S Somkuwar, Chloe J Jordan, Kathleen M Kantak, Linda P Dwoskin. Adolescent atomoxetine treatment in a rodent model of ADHD: effects on cocaine self-administration and dopamine transporters in frontostriatal regions. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2013 Dec; 38(13):2588-97. doi: 10.1038/npp.2013.163. [PMID: 23822950]
  • D-W Shang, W Guo, F-C Zhou, X-P Wang, A-N Li, L Zhang, W-B Li, W Lu, C-Y Wang. Relative bioequivalence evaluation of two oral atomoxetine hydrochloride capsules: a single dose, randomized, open-label, 2-period crossover study in healthy Chinese volunteers under fasting conditions. Drug research. 2013 Nov; 63(11):564-7. doi: 10.1055/s-0033-1349070. [PMID: 23812961]
  • Elizabeth A Green, Vidya Raj, Cyndya A Shibao, Italo Biaggioni, Bonnie K Black, William D Dupont, David Robertson, Satish R Raj. Effects of norepinephrine reuptake inhibition on postural tachycardia syndrome. Journal of the American Heart Association. 2013 Sep; 2(5):e000395. doi: 10.1161/jaha.113.000395. [PMID: 24002370]
  • Angelo Camporeale, Kathleen Ann Day, Dustin Ruff, Jody Arsenault, David Williams, Douglas K Kelsey. Profile of sexual and genitourinary treatment-emergent adverse events associated with atomoxetine treatment: a pooled analysis. Drug safety. 2013 Aug; 36(8):663-71. doi: 10.1007/s40264-013-0074-2. [PMID: 23775507]
  • Li Yang, Qiujin Qian, Lu Liu, Haimei Li, Stephen V Faraone, Yufeng Wang. Adrenergic neurotransmitter system transporter and receptor genes associated with atomoxetine response in attention-deficit hyperactivity disorder children. Journal of neural transmission (Vienna, Austria : 1996). 2013 Jul; 120(7):1127-33. doi: 10.1007/s00702-012-0955-z. [PMID: 23266789]
  • Esther Papaseit, Emilia Marchei, Magí Farré, Oscar Garcia-Algar, Roberta Pacifici, Simona Pichini. Concentrations of atomoxetine and its metabolites in plasma and oral fluid from paediatric patients with attention deficit/hyperactivity disorder. Drug testing and analysis. 2013 Jun; 5(6):446-52. doi: 10.1002/dta.1370. [PMID: 22589233]
  • Sharon L Walsh, Lisa S Middleton, Conrad J Wong, Paul A Nuzzo, Charles L Campbell, Craig R Rush, Michelle R Lofwall. Atomoxetine does not alter cocaine use in cocaine dependent individuals: double blind randomized trial. Drug and alcohol dependence. 2013 Jun; 130(1-3):150-7. doi: 10.1016/j.drugalcdep.2012.10.024. [PMID: 23200303]
  • Cho-Ming Loi, Dennis A Smith, Deepak Dalvie. Which metabolites circulate?. Drug metabolism and disposition: the biological fate of chemicals. 2013 May; 41(5):933-51. doi: 10.1124/dmd.112.050278. [PMID: 23454828]
  • Himanshu P Upadhyaya, Durisala Desaiah, Kory J Schuh, Frank P Bymaster, Mary J Kallman, David O Clarke, Todd M Durell, Paula T Trzepacz, David O Calligaro, Eric S Nisenbaum, Paul J Emmerson, Leslie M Schuh, Warren K Bickel, Albert J Allen. A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder. Psychopharmacology. 2013 Mar; 226(2):189-200. doi: 10.1007/s00213-013-2986-z. [PMID: 23397050]
  • Corina Loghin, Harry Haber, Charles M Beasley, Prajakti A Kothare, Lynnette Kauffman, John April, Ling Jin, Albert J Allen, Malcolm I Mitchell. Effects of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers. British journal of clinical pharmacology. 2013 Feb; 75(2):538-49. doi: 10.1111/j.1365-2125.2012.04382.x. [PMID: 22803597]
  • M Reza Mirbolooki, Cristian C Constantinescu, Min-Liang Pan, Jogeshwar Mukherjee. Targeting presynaptic norepinephrine transporter in brown adipose tissue: a novel imaging approach and potential treatment for diabetes and obesity. Synapse (New York, N.Y.). 2013 Feb; 67(2):79-93. doi: 10.1002/syn.21617. [PMID: 23080264]
  • Thomas Lempp, Stefan W Toennes, Cora Wunder, Otto Quintus Russe, Christine V Möser, Katharina L Kynast, Christine M Freitag, Ellen Niederberger. Altered gene expression in the prefrontal cortex of young rats induced by the ADHD drug atomoxetine. Progress in neuro-psychopharmacology & biological psychiatry. 2013 Jan; 40(?):221-8. doi: 10.1016/j.pnpbp.2012.08.012. [PMID: 22960082]
  • Fei Shen, Pamela R Tsuruda, Jacqueline A M Smith, Glenmar P Obedencio, William J Martin. Relative contributions of norepinephrine and serotonin transporters to antinociceptive synergy between monoamine reuptake inhibitors and morphine in the rat formalin model. PloS one. 2013; 8(9):e74891. doi: 10.1371/journal.pone.0074891. [PMID: 24098676]
  • Adriana Alexandre dos Santos Tavares, Olivier Barret, Jeffery Batis, David Alagille, Andrei Koren, Caroline Papin, Greg Kudej, Katie Nice, Jeffrey H Kordower, Kelly P Cosgrove, Tracy Kloczynski, Eric Brenner, John Seibyl, Gilles Tamagnan. Kinetic modeling and occupancy measures of the norepinephrine transporters in baboons using single photon emission computed tomography with (123)I-INER. Synapse (New York, N.Y.). 2013 Jan; 67(1):30-41. doi: 10.1002/syn.21613. [PMID: 23042643]
  • Patrick T Udvardi, Karl J Föhr, Carolin Henes, Stefan Liebau, Jens Dreyhaupt, Tobias M Boeckers, Andrea G Ludolph. Atomoxetine affects transcription/translation of the NMDA receptor and the norepinephrine transporter in the rat brain--an in vivo study. Drug design, development and therapy. 2013; 7(?):1433-46. doi: 10.2147/dddt.s50448. [PMID: 24348020]
  • David I Appel, Bryan Brinda, John S Markowitz, Jeffrey H Newcorn, Hao-Jie Zhu. A liquid chromatography/tandem mass spectrometry assay for the analysis of atomoxetine in human plasma and in vitro cellular samples. Biomedical chromatography : BMC. 2012 Nov; 26(11):1364-70. doi: 10.1002/bmc.2706. [PMID: 22275222]
  • Christopher Steer, Jan Froelich, César A Soutullo, Mats Johnson, Monica Shaw. Lisdexamfetamine dimesylate: a new therapeutic option for attention-deficit hyperactivity disorder. CNS drugs. 2012 Aug; 26(8):691-705. doi: 10.2165/11634340-000000000-00000. [PMID: 22762726]
  • Cheryl Shuang-wu Li, Liming Zhang, Taraneh Haske, Amy Dounay, David Gray, Nancy Barta, Joanne Brodfuehrer, Christopher Lepsy, Brian Campbell. Mechanism-based pharmacokinetic/pharmacodynamic modeling of rat prefrontal cortical dopamine response to dual acting norepinephrine reuptake inhibitor and 5-HT1A partial agonist. The AAPS journal. 2012 Jun; 14(2):365-76. doi: 10.1208/s12248-012-9343-8. [PMID: 22454087]
  • Luis E Okamoto, Cyndya Shibao, Alfredo Gamboa, Leena Choi, André Diedrich, Satish R Raj, Bonnie K Black, David Robertson, Italo Biaggioni. Synergistic effect of norepinephrine transporter blockade and α-2 antagonism on blood pressure in autonomic failure. Hypertension (Dallas, Tex. : 1979). 2012 Mar; 59(3):650-6. doi: 10.1161/hypertensionaha.111.184812. [PMID: 22311903]
  • A Matsui, J Azuma, J W Witcher, A J Long, J-M Sauer, B P Smith, K A DeSante, H A Read, M Takahashi, M Nakano. Pharmacokinetics, safety, and tolerability of atomoxetine and effect of CYP2D6*10/*10 genotype in healthy Japanese men. Journal of clinical pharmacology. 2012 Mar; 52(3):388-403. doi: 10.1177/0091270011398657. [PMID: 21543662]
  • Michael G Ziegler, Milos Milic. New therapies for postural hypotension. Hypertension (Dallas, Tex. : 1979). 2012 Mar; 59(3):548-9. doi: 10.1161/hypertensionaha.111.187278. [PMID: 22311904]
  • Emilia Marchei, Esther Papaseit, Oscar Q Garcia-Algar, Magi Farrè, Roberta Pacifici, Simona Pichini. Determination of atomoxetine and its metabolites in conventional and non-conventional biological matrices by liquid chromatography-tandem mass spectrometry. Journal of pharmaceutical and biomedical analysis. 2012 Feb; 60(?):26-31. doi: 10.1016/j.jpba.2011.11.009. [PMID: 22142618]
  • Chang-Ik Choi, Jung-Woo Bae, Hye-In Lee, Choon-Gon Jang, Uy Dong Sohn, Seok-Yong Lee. Determination of atomoxetine metabolites in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2012 Feb; 885-886(?):103-8. doi: 10.1016/j.jchromb.2011.12.023. [PMID: 22237133]
  • Shankar Sadasivan, Brooks B Pond, Amar K Pani, Chunxu Qu, Yun Jiao, Richard J Smeyne. Methylphenidate exposure induces dopamine neuron loss and activation of microglia in the basal ganglia of mice. PloS one. 2012; 7(3):e33693. doi: 10.1371/journal.pone.0033693. [PMID: 22470460]
  • Kenshi Takechi, Katsuya Suemaru, Hiromu Kawasaki, Hiroaki Araki. Regulatory role of the dopamine and norepinephrine transporters in pentylenetetrazol-kindled mice: association with effect of antidepressants. European journal of pharmacology. 2011 Dec; 673(1-3):33-9. doi: 10.1016/j.ejphar.2011.10.017. [PMID: 22044920]
  • Tarun Dua, Corrado Barbui, Nicolas Clark, Alexandra Fleischmann, Vladimir Poznyak, Mark van Ommeren, M Taghi Yasamy, Jose Luis Ayuso-Mateos, Gretchen L Birbeck, Colin Drummond, Melvyn Freeman, Panteleimon Giannakopoulos, Itzhak Levav, Isidore S Obot, Olayinka Omigbodun, Vikram Patel, Michael Phillips, Martin Prince, Afarin Rahimi-Movaghar, Atif Rahman, Josemir W Sander, John B Saunders, Chiara Servili, Thara Rangaswamy, Jürgen Unützer, Peter Ventevogel, Lakshmi Vijayakumar, Graham Thornicroft, Shekhar Saxena. Evidence-based guidelines for mental, neurological, and substance use disorders in low- and middle-income countries: summary of WHO recommendations. PLoS medicine. 2011 Nov; 8(11):e1001122. doi: 10.1371/journal.pmed.1001122. [PMID: 22110406]
  • David J O'Neill, Adedayo Adedoyin, Jenifer A Bray, Darlene C Deecher, Andrew Fensome, Joel A Goldberg, Jim Harrison, Liza Leventhal, Charles Mann, Lilly Mark, Lisa Nogle, Nicole R Sullivan, Taylor B Spangler, Eugene A Terefenko, Eugene J Trybulski, Albert J Uveges, An Vu, Garth T Whiteside, Puwen Zhang. Discovery of novel selective norepinephrine inhibitors: 1-(2-morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxides (WYE-114152). Journal of medicinal chemistry. 2011 Oct; 54(19):6824-31. doi: 10.1021/jm200733r. [PMID: 21916421]
  • Michael H Bloch, Ahmad Qawasmi. Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis. Journal of the American Academy of Child and Adolescent Psychiatry. 2011 Oct; 50(10):991-1000. doi: 10.1016/j.jaac.2011.06.008. [PMID: 21961774]
  • Cheryl R Stein, David A Savitz. Serum perfluorinated compound concentration and attention deficit/hyperactivity disorder in children 5-18 years of age. Environmental health perspectives. 2011 Oct; 119(10):1466-71. doi: 10.1289/ehp.1003538. [PMID: 21665566]
  • T J Renner, T T Nguyen, M Romanos, S Walitza, C Röser, A Reif, H Schäfer, A Warnke, M Gerlach, K P Lesch. No evidence for association between a functional promoter variant of the Norepinephrine Transporter gene SLC6A2 and ADHD in a family-based sample. Attention deficit and hyperactivity disorders. 2011 Sep; 3(3):285-9. doi: 10.1007/s12402-011-0060-4. [PMID: 21739117]
  • Dong-Ho Song, Kyungun Jhung, Jungeun Song, Keun-Ah Cheon. The 1287 G/A polymorphism of the norepinephrine transporter gene (NET) is involved in commission errors in Korean children with attention deficit hyperactivity disorder. Behavioral and brain functions : BBF. 2011 May; 7(?):12. doi: 10.1186/1744-9081-7-12. [PMID: 21569456]
  • Jean-Dominique Gallezot, David Weinzimmer, Nabeel Nabulsi, Shu-Fei Lin, Krista Fowles, Christine Sandiego, Timothy J McCarthy, R Paul Maguire, Richard E Carson, Yu-Shin Ding. Evaluation of [(11)C]MRB for assessment of occupancy of norepinephrine transporters: Studies with atomoxetine in non-human primates. NeuroImage. 2011 May; 56(1):268-79. doi: 10.1016/j.neuroimage.2010.09.040. [PMID: 20869448]
  • Marty Hinz, Alvin Stein, Robert Neff, Robert Weinberg, Thomas Uncini. Treatment of attention deficit hyperactivity disorder with monoamine amino acid precursors and organic cation transporter assay interpretation. Neuropsychiatric disease and treatment. 2011 Jan; 7(?):31-8. doi: 10.2147/ndt.s16270. [PMID: 21326653]
  • Yosefu Arime, Yumiko Kubo, Ichiro Sora. Animal models of attention-deficit/hyperactivity disorder. Biological & pharmaceutical bulletin. 2011; 34(9):1373-6. doi: 10.1248/bpb.34.1373. [PMID: 21881220]
  • Alonso Montoya, Rodrigo Escobar, María J García-Polavieja, D Richard Lachno, José Ángel Alda, Josep Artigas, Esther Cardo, Marta García, Xavier Gastaminza, Inmaculada Gilaberte. Changes of urine dihydroxyphenylglycol to norepinephrine ratio in children with attention-deficit hyperactivity disorder (ADHD) treated with atomoxetine. Journal of child neurology. 2011 Jan; 26(1):31-6. doi: 10.1177/0883073810371981. [PMID: 20525942]
  • Kate Hoffman, Thomas F Webster, Marc G Weisskopf, Janice Weinberg, Verónica M Vieira. Exposure to polyfluoroalkyl chemicals and attention deficit/hyperactivity disorder in U.S. children 12-15 years of age. Environmental health perspectives. 2010 Dec; 118(12):1762-7. doi: 10.1289/ehp.1001898. [PMID: 20551004]
  • Boong-Nyun Kim, Jae-Won Kim, Soon Beom Hong, Soo-Churl Cho, Min-Sup Shin, Hee-Jeong Yoo. Possible association of norepinephrine transporter -3081(A/T) polymorphism with methylphenidate response in attention deficit hyperactivity disorder. Behavioral and brain functions : BBF. 2010 Oct; 6(?):57. doi: 10.1186/1744-9081-6-57. [PMID: 20929549]
  • Yong Wook Kim, Ji-Cheol Shin, Young-Sil An. Treatment of chronic akinetic mutism with atomoxetine: subtraction analysis of brain f-18 fluorodeoxyglucose positron emission tomographic images before and after medication: a case report. Clinical neuropharmacology. 2010 Jul; 33(4):209-11. doi: 10.1097/wnf.0b013e3181dca948. [PMID: 20661027]
  • Michael A Siuta, Sabrina D Robertson, Heidi Kocalis, Christine Saunders, Paul J Gresch, Vivek Khatri, Chiyo Shiota, J Philip Kennedy, Craig W Lindsley, Lynette C Daws, Daniel B Polley, Jeremy Veenstra-Vanderweele, Gregg D Stanwood, Mark A Magnuson, Kevin D Niswender, Aurelio Galli. Dysregulation of the norepinephrine transporter sustains cortical hypodopaminergia and schizophrenia-like behaviors in neuronal rictor null mice. PLoS biology. 2010 Jun; 8(6):e1000393. doi: 10.1371/journal.pbio.1000393. [PMID: 20543991]
  • Andrea G Ludolph, Patrick T Udvardi, Ulrike Schaz, Carolin Henes, Oliver Adolph, Henry U Weigt, Joerg M Fegert, Tobias M Boeckers, Karl J Föhr. Atomoxetine acts as an NMDA receptor blocker in clinically relevant concentrations. British journal of pharmacology. 2010 May; 160(2):283-91. doi: 10.1111/j.1476-5381.2010.00707.x. [PMID: 20423340]